{"id":12104,"date":"2024-11-11T15:54:25","date_gmt":"2024-11-11T07:54:25","guid":{"rendered":"https:\/\/flcube.com\/?p=12104"},"modified":"2024-11-11T15:54:27","modified_gmt":"2024-11-11T07:54:27","slug":"gilead-sciences-reports-7-yoy-increase-in-q3-2024-product-sales-driven-by-hiv-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=12104","title":{"rendered":"Gilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies"},"content":{"rendered":"\n

Gilead Sciences Inc., (NASDAQ: GILD<\/a>), a major US-based pharmaceutical company, has released its financial results for the third quarter of 2024, showing a 7% year-on-year (YOY) increase in product sales to USD 7.515 billion. Excluding sales of the COVID-19 drug Veklury (remdesivir), the figure stands at a 7% YOY increase to USD 6.823 billion.<\/p>\n\n\n\n

Product Growth and Portfolio Performance<\/strong>
The growth in product sales was primarily driven by HIV therapies, with related sales up 9% YOY to USD 5.073 billion. The Liver Disease portfolio sales increased by 4% to USD 733 million in Q3 2024, while Oncology sales grew by 6% YOY to USD 816 million. Conversely, sales of other products and licensing collaboration business declined by 7% and 46%, respectively, to USD 201 million and USD 30 million.<\/p>\n\n\n\n

Key Product Sales Contributions<\/strong>
HIV therapy Biktarvy (bictegravir\/emtricitabine\/tenofovir alafenamide) led the way with a 13% increase in sales to USD 3.5 billion in Q3 2024, with the US market accounting for 80% of this figure. The COVID-19 drug Remdesivir contributed USD 692 million in sales, showing a continued downward trend. Another HIV therapy, Descovy (emtricitabine\/tenofovir alafenamide fumarate), recorded sales of USD 586 million. In oncology, cell therapies Tecartus and Yescarta together generated USD 485 million, though this was flat compared to the same period last year. Antibody drug conjugates (ADCs) achieved sales of USD 332 million, marking a 17% YOY increase.<\/p>\n\n\n\n

Company Outlook and Guidance Update<\/strong>
Daniel O\u2019Day, Gilead\u2019s Chairman and Chief Executive Officer, commented, \u201cBased on this very strong topline growth and disciplined operating expense management, we are increasing our full year revenue, operating income, and earnings per share guidance.\u201d He added, \u201cWe are excited to further increase our impact for patients and communities in the months ahead. This includes building on the momentum from the U.S. launch of Livdelzi for primary biliary cholangitis and preparing for the potential launch of the first twice-yearly option for HIV prevention, lenacapavir.\u201d-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Gilead Sciences Inc., (NASDAQ: GILD), a major US-based pharmaceutical company, has released its financial results…<\/p>\n","protected":false},"author":1,"featured_media":12105,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,226,1025],"class_list":["post-12104","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-gilead-sciences","tag-nasdaq-gild"],"yoast_head":"\nGilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Gilead Sciences Inc., (NASDAQ: GILD), a major US-based pharmaceutical company, has released its financial results for the third quarter of 2024, showing a 7% year-on-year (YOY) increase in product sales to USD 7.515 billion. Excluding sales of the COVID-19 drug Veklury (remdesivir), the figure stands at a 7% YOY increase to USD 6.823 billion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=12104\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=12104\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-11T07:54:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-11T07:54:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/a2ab81a2ef9ed8d55e7ab0b40c39cef8.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12104#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12104\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies\",\"datePublished\":\"2024-11-11T07:54:25+00:00\",\"dateModified\":\"2024-11-11T07:54:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12104\"},\"wordCount\":317,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12104#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/a2ab81a2ef9ed8d55e7ab0b40c39cef8.jpeg\",\"keywords\":[\"Finanical Reports\",\"Gilead Sciences\",\"NASDAQ: GILD\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12104#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12104\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=12104\",\"name\":\"Gilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12104#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12104#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/a2ab81a2ef9ed8d55e7ab0b40c39cef8.jpeg\",\"datePublished\":\"2024-11-11T07:54:25+00:00\",\"dateModified\":\"2024-11-11T07:54:27+00:00\",\"description\":\"Gilead Sciences Inc., (NASDAQ: GILD), a major US-based pharmaceutical company, has released its financial results for the third quarter of 2024, showing a 7% year-on-year (YOY) increase in product sales to USD 7.515 billion. Excluding sales of the COVID-19 drug Veklury (remdesivir), the figure stands at a 7% YOY increase to USD 6.823 billion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12104#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12104\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12104#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/a2ab81a2ef9ed8d55e7ab0b40c39cef8.jpeg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/a2ab81a2ef9ed8d55e7ab0b40c39cef8.jpeg\",\"width\":2560,\"height\":1440,\"caption\":\"Gilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12104#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies - Insight, China's Pharmaceutical Industry","description":"Gilead Sciences Inc., (NASDAQ: GILD), a major US-based pharmaceutical company, has released its financial results for the third quarter of 2024, showing a 7% year-on-year (YOY) increase in product sales to USD 7.515 billion. Excluding sales of the COVID-19 drug Veklury (remdesivir), the figure stands at a 7% YOY increase to USD 6.823 billion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=12104","og_locale":"en_US","og_type":"article","og_title":"Gilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=12104","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-11-11T07:54:25+00:00","article_modified_time":"2024-11-11T07:54:27+00:00","og_image":[{"width":2560,"height":1440,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/a2ab81a2ef9ed8d55e7ab0b40c39cef8.jpeg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=12104#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=12104"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies","datePublished":"2024-11-11T07:54:25+00:00","dateModified":"2024-11-11T07:54:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=12104"},"wordCount":317,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=12104#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/a2ab81a2ef9ed8d55e7ab0b40c39cef8.jpeg","keywords":["Finanical Reports","Gilead Sciences","NASDAQ: GILD"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=12104#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=12104","url":"https:\/\/flcube.com\/?p=12104","name":"Gilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=12104#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=12104#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/a2ab81a2ef9ed8d55e7ab0b40c39cef8.jpeg","datePublished":"2024-11-11T07:54:25+00:00","dateModified":"2024-11-11T07:54:27+00:00","description":"Gilead Sciences Inc., (NASDAQ: GILD), a major US-based pharmaceutical company, has released its financial results for the third quarter of 2024, showing a 7% year-on-year (YOY) increase in product sales to USD 7.515 billion. Excluding sales of the COVID-19 drug Veklury (remdesivir), the figure stands at a 7% YOY increase to USD 6.823 billion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=12104#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=12104"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=12104#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/a2ab81a2ef9ed8d55e7ab0b40c39cef8.jpeg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/a2ab81a2ef9ed8d55e7ab0b40c39cef8.jpeg","width":2560,"height":1440,"caption":"Gilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=12104#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/a2ab81a2ef9ed8d55e7ab0b40c39cef8.jpeg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12104"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12104\/revisions"}],"predecessor-version":[{"id":12106,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12104\/revisions\/12106"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/12105"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12104"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12104"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}